MSD has received approval from China's National Medical Products Administration (NMPA) to extend the use of Prevymis (letermovir) for cytomegalovirus (CMV) prevention to 200 days post-hematopoietic stem cell transplant (HSCT) in adults at risk of late-onset infection. The oral and intravenous formulations of this non-nucleoside CMV inhibitor were previously limited to 100-day prophylaxis. Clinical data showed 12% of patients developed clinically significant CMV infections after stopping Prevymis at 100 days, prompting this label expansion.

Prevymis remains the only approved CMV prophylactic for HSCT recipients aged 6 months and above in China. The drug is listed in China's National Reimbursement Drug Directory for CMV-seropositive adult HSCT patients. MSD China President Kyle Tattle highlighted its role in personalised CMV management. The approval follows MSD's recent paediatric expansion for Prevymis in China.

PharmCube's NextBiopharm® database lists 67 CMV innovative drug programs currently active and developed by 72 companies, including a number of Big Pharmas. Click here to request a free trial for NextBiopharm®.